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ABSTRACT Multiple primary melanoma (MPM) is a well-known phe-
nomenon, but outcome studies regarding patients with MPM are rare. 
Aim of our study was to analyze whether MPM are less likely to metasta-
size than single primary melanomas (SPM). In our study disease progres-
sion (defined by the occurrence of regional lymph node or distant me-
tastases) in cases of MPM was compared to cases of SPM on a sample of 
1698 melanomas. Statistically significant difference in the occurrence of 
disease progression was found between the analyzed groups, progres-
sion being significantly less frequent in patients with MPM (P=0.009). 
Also, MPM occurred significantly more frequently in male patients (P= 
0.001). 
We attribute these results not only to early detection of subsequent 
MPM, but to a variety of possible reasons, including different genetics 
and biology of tumors and, possibly, the immune response of the host. 
Further studies are required to elucidate these interesting findings.
KEY WORDS: melanoma, multiple primary melanoma, disease progres-
sion
INTRODUCTION
There have been a number of studies on the phe-
nomenon of multiple primary melanomas (MPM), es-
pecially over the last decades. According to various 
studies, the risk of developing an additional primary 
tumor in patients who have already been diagnosed 
with primary melanoma ranges from 0.6% to 12.7% 
(1-9). Many aspects of MPM have been investigated, 
including their epidemiological and clinical proper-
ties, clinicopathologic differences between first and 
subsequent melanomas in people with MPM, as well 
as dermoscopic features of MPM (10-12). However, 
outcome and prognosis studies regarding MPM are 
rare.
An association has been found between MPM and 
other malignant diseases, leading to a proposition of 
common genetic or environmental factors (10). How-
ever, the most relevant findings in that study are the 
disease-free survival curves of MPM and single pri-
mary melanoma (SPM) patients, which did not differ 
significantly, and survival curves, which inexplicably 
favored patients with MPM (10). The latest multi-
center study reported an increased risk of death with 
increasing tumor thickness in patients with SPM com-
pared with patients with MPM (13). To unravel some 
more details about this fact, we analyzed individual 
melanoma cases in patients with both MPM and SPM 
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and compared the frequency of disease progression 
between those two groups. The aim of this study was 
to determine whether the tumors in patients with 
MPM are less likely to metastasize than those in pa-
tients with SPM.
PATIENTS AND METHODS
In this study, we focused on melanoma cases per 
se, rather than on the number of patients with mela-
noma, as it provided us with an opportunity to as-
sess the frequency of disease progression for each 
individual tumor. The cases of melanoma were taken 
from the database of the Croatian Referral Melanoma 
Centre (Department of Dermatovenereology, Sestre 
milosrdnice University Hospital Centre, Zagreb, Croa-
tia), and melanoma cases (of consecutively diagnosed 
patients) evidenced in the Referral Melanoma Centre 
during a 11-year-period (2002-2012) were analyzed. 
Histopathological data about tumors was obtained 
from the histopathological reports, and clinical data 
(age, sex, follow-up, and the occurrence of disease 
progression) was obtained from the department 
charts. The study was carried out in compliance with 
the Helsinki Declaration and approved by the institu-
tion’s ethics committee.  
After exclusion criteria (incomplete data, melano-
ma of unknown primary origin, primary melanoma of 
the eye, patients who received adjuvant therapy after 
the diagnosis of the first primary melanoma) were 
met, 1698 cases of melanoma remained, of which 164 
(9.65%) appeared alongside other primary melano-
mas in 72 patients with MPM. To avoid early detection 
bias, we added to exclusion criteria the early stages 
of melanoma (melanoma in situ (MIS) and Breslow I 
tumors of <0.75 mm thickness) when they would 
have been unlikely to produce metastases. Most of 
the patients with MPM had 2 melanomas (56 pa-
tients, 77.77%). There were 10 (13.88%) patients with 
3 MPM, 2 (2.77%) patients with 4 MPM, and 4 (5.54%) 
patients with 5 or more MPM. The highest number of 
primary tumors in one patient was 16. 
Cases of melanoma were divided in two groups, 
with cases of melanoma in patients with multiple pri-
maries in the first group, and single primary melano-
mas as controls in the second group. We compared the 
disease progression in cases of MPM with the cases in 
patients with SPM. The disease progression was de-
fined by the detection of regional lymph node or dis-
tant cutaneous, subcutaneous or visceral metastases. 
The follow up protocol was the same for both groups, 
with the frequency of examinations (clinical exami-
nation, laboratory examinations, ultrasound of the 
regional lymph nodes and abdomen, chest X-ray, and 
CT or PET/CT scans) depending on the primary tumor 
thickness/the thickest primary melanoma thickness 
and stage of the disease. The mean follow up of this 
cohort was 58.16 months, and the median follow-up 
was 60 months. The shortest follow-up was 6 months, 
and the longest follow-up was 194 months.
Statistical analysis 
Differences in the frequency of disease progres-
sion in both case and control groups (MPM and SPM) 
were assessed using the χ2 test. The underlying char-
acteristics of both the case and control group and 
the differences between categorical variables were 
analyzed using the Student t-test. The level of signifi-
cance was set at P<0.05 in all cases. All analyses were 
performed with MedCalc for Windows, version 11.3 
(www.medcalc.be).
RESULTS
The clinicopathologic data of all patients with 
MPM and SPM are shown in Table 1. Analysis of all 
melanoma cases (N=1698) showed that there was no 
significant difference in tumor thickness (P=0.188) 
and follow-up period (P=0.501) between MPM and 
SPM. A significant difference was noticed in the age 
of patients with melanoma, with patients with MPM 
being older than those with SPM (P=0.028) (Table 1). 
The mean tumor thickness of the first melanoma 
Table 1. Clinicopathologic characteristics of all patients with multiple primary melanomas (MPM) and single 
primary melanoma (SPM) (N=1698)
Cases (MPM) Controls (SPM) P-value
Number of cases 164 1534
Patient age mean (years) 58.08 ± 14.79 54.42±15.29 0.028
Women/Men 25 (34.72%)/47(65.28%) 837 (54.56%)/697 (45.44%) 0.001
Thickness mean (mm) 1.87 ± 3.82 2.22±2.79 0.188
Number of disseminated melanomas 5 (3.04%) 189 (12.32%) 0.001
Follow-up mean (months) 59.53 56.80 0.501
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diagnosed in the MPM group was 2.68±5.29 mm, 
whereas the mean tumor thickness in the SPM group 
was 2.22±2.79 mm, P=0.521. The mean tumor thick-
ness of all subsequently diagnosed melanomas in the 
MPM group was 1.29 mm.
Furthermore, the analysis of all melanoma cases 
in the study (N=1698) showed that in the control 
group (SPM) disease progression occurred in 189 out 
of 1534 cases (12.32%), whereas in the case group 
(MPM), disease progression occurred in 5 out of 164 
cases (3.04%). The difference in the occurrence of dis-
ease progression between these two groups was sta-
tistically significant (P<0.0001) (Table 1). 
To avoid early detection bias, we added to exclu-
sion criteria the early stages of melanoma (melanoma 
in situ (MIS) and Breslow I tumors) when they would 
have been unlikely to produce metastases. After the 
exclusion of all MIS and Breslow I tumours, 75 mela-
noma cases in the case group and 963 cases in the 
control group remained (Table 2). 
After exclusion of all MIS and Breslow I melano-
mas, the results also showed no significant difference 
in tumor thickness (P=0.776) and follow-up period 
(P=0.882) between MPM and SPM, as well as no sig-
nificant difference in the age of patients (P=0.077) 
(Table 2). In addition, disease progression in the con-
trol group (SPM) occurred in 189 out of 963 cases 
(19.62%), whereas in the case group (MPM), disease 
progression occurred in 5 out of 75 cases (6.67%). The 
difference in the occurrence of disease progression 
between these two groups was still statistically sig-
nificant (P=0.003) (Table 2).
The difference in the occurrence of MPM accord-
ing to gender distribution was statistically significant 
before and after excluding early stage melanomas 
(P=0.001 and P=0.012, respectively), with MPM occur-
ring significantly more often in male than in female 
patients (Table 1, Table 2).
DISCUSSION
Patients who have already been diagnosed with 
one primary melanoma have a substantially in-
creased risk of developing further primary melano-
mas, ranging from 0.6% to 12.7% in different studies 
(1,3,4,8,10,14,15). The most important risk factors as-
sociated with the development of MPM seem to be 
positive family history of melanoma and the pres-
ence of atypical nevi (7,16-18). Generally, people with 
numerous atypical moles and a family or personal 
history of melanoma are at the greatest risk for devel-
oping cutaneous melanoma. Patients from this popu-
lation tend to develop melanoma approximately 10 
years earlier than the general population and have an 
increased risk for developing MPM (19). It has been 
shown that the risk of subsequent melanoma is the 
highest within the first two years after the first mela-
noma being diagnosed (8,10).
Even though the occurrence of MPM is a well-
documented phenomenon, studies on the prog-
nostic implications in such patients are rare (13,20). 
Only a few studies exist analyzing a large number of 
cases, all of which observed that patients with MPM 
have the same, or even better prognosis compared 
to  their SPM counterparts (10,13). This has always 
been very confounding, as it would be reasonable 
to expect that two independent malignant diseases 
would be more prone to progression and poor out-
come than a single one.This was attributed mainly 
to the assumption that, after being diagnosed with 
the first primary melanoma, patients remain under 
regular dermatological follow-up and self-examina-
tion, and generally behave more photoprotectively. 
Therefore, subsequent melanomas in such patients 
would be discovered at early stage of the disease, 
when chances for disease progression would be ac-
cordingly smaller (21-23).
In the current study, we analyzed the frequency 
of disease progression (defined by the detection of 
regional lymph nodes or distant cutaneous, subcu-
taneous, or visceral metastases) in a large, relatively 
homologous cohort of MPM and SPM specimens with 
defined histological features, clinical data, and follow 
up. 
In our research, we tried to circumvent the po-
tential bias of early melanoma detection by exclud-
Table 2. Clinicopathologic characteristics of patients with multiple primary melanomas (MPM) and single 
primary melanoma (SPM) after the exclusion of all melanoma in situ and Breslow I tumours (N=1038)
Cases (MPM) Controls (SPM) P-value
Number of cases 75 963
Patient age mean (years) 58.64±13.48 55.02±15.33 0.077
Women/Men 20 (33.90%)/39 (66.10%) 497 (51.60%)/466 (48.40%) 0.012
Tumor thickness mean (mm) 2.92 3.03 0.776
Number of disseminated melanomas 5 (6.66%) 189 (19.62%) 0.009
Follow-up mean (months) 60.36 59.76 0.882
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ing all the melanoma cases in early stages, leaving 
melanoma cases of similar mean thickness and Bre-
slow stage in both the case (MPM) and control (SPM) 
groups. Additionally, we focused on melanoma cases 
per se rather than on the number of patients with 
melanoma, as it provided us with an opportunity to 
assess the frequency of propagation for each individ-
ual tumor. This enabled us to investigate the curious 
finding that there is no difference in disease-free sur-
vival between patients with a single malignant tumor 
and those with two or more. Clearly, this is surprising, 
as every subsequent tumor that the patient acquires 
should deteriorate the chance of long-term disease-
free survival. The results of our study suggest that 
melanomas which occur in people with MPM metas-
tasize statistically significantly less frequently than 
tumors in people with SPM. 
The latest multicenter study which explored sur-
vival in a large population-based sample of patients 
with SPM and MPM of any stage reported an in-
creased risk of death with increasing tumor thickness 
(which was the main determinant of fatality in the 
analysis) which was higher in patients with SPM than 
in patients with MPM (13). Although overall fatalities 
due to SPM and MPM were similar, relative fatality for 
thicker SPM was greater than for thicker MPM. This 
finding may indicate that the difference in the out-
come between patients with SPM and MPM might be 
related to factors other than closer surveillance and 
earlier diagnosis (13). However, in our study, no sta-
tistically significant difference in tumor thickness be-
tween SPM and MPM cases was found (which could 
have influenced the difference in the occurrence of 
metastases), however, the incidence of disease pro-
gression was significantly higher in the cases of SPM 
than in MPM. On the other hand, other clinicopatho-
logic parameters, such as anatomical localization of 
the primary tumors, mitotic rate, and ulceration were 
not included in the current study and might play a 
role in the differences seen between the analyzed 
groups.
Additionally, the results of our study showed that 
MPM occur significantly more often in male than in 
female patients. This was not deemed a potential 
source of bias when assessing the differences in dis-
ease progression, as male sex was found to be a risk 
factor leading to worse outcome of the disease (20), 
and in our research we saw a tendency towards bet-
ter outcomes in the group with a higher percentage 
of male patients. It is also uncertain why there would 
be a higher occurrence of MPM in male patients, and 
other studies have not duplicated this finding (10,11). 
It is unlikely that this is a result of higher disease 
awareness in females or better follow-up after first 
melanoma, as this has no effect on the development 
of the next melanoma, influencing rather its discov-
ery in the early stage. It is possible that the significant 
difference in gender distribution of MPM frequency 
is a result of better sun protection and self-examina-
tions in female patients after being diagnosed with 
their first melanoma. 
CONCLUSION
The reason as to why two tumors, otherwise con-
sidered to be equally aggressive, would behave dif-
ferently in people that have only one of them than in 
people with two or more tumors of the same type, is 
uncertain. Possibly, the genetic error in the cascade 
that leads to melanoma development is different, in 
one variety leading to one more malignant tumor 
and to multiple less aggressive tumors in another. 
Another explanation might be that the immune sys-
tem learns from the first melanoma, which enables it 
to react more efficiently to the next one. A possibility 
has been suggested that patients with rapidly pro-
gressing single primary melanoma die before they 
have had enough time to develop subsequent mela-
nomas, skewing the statistics towards poor outcome 
in SPM (10). Either way, further research is needed to 
clarify this intriguing prognostic finding in patients 
with MPM, as well as the fact that MPM seems to 
be occurring more often in male than in female pa-
tients.
References:
1. Pack GT, Scharnagel IM, Hillyer RA. Multiple pri-
mary melanoma. Cancer 1952;5:1110-5.
2. Allen AC, Spitz S. Malignant melanoma; a clinico-
pathological analysis of the criteria for diagnosis 
and prognosis. Cancer 1953;6:1-45.
3. Beardmore GL, Davis NC. Multiple primary cuta-
neous melanomas. Arch Dermatol 1975;111:603-
9.
4. Beardmore GL. The Queensland melanoma pro-
ject. Int J Dermatol 1977;16:831-5.
5. Moseley HS, Giuliano AE, Storm FK 3rd, Clark WH, 
Robinson DS, Morton DL. Multiple primary mela-
noma. Cancer 1979;43:939-44.
6. Savoia P, Quaglino P, Verrone A, Bernengo MG. 
Multiple primary melanomas: analysis of 49 cases. 
Melanoma Res 1998;8:361-6.
7. Ferrone CR, Ben Porat L, Panageas KS, Berwick M, 
Halpern AC, Patel A, et al. Clinicopathological fea-
tures of and risk factors for multiple primary me-
lanomas. JAMA 2005;294:1647-54.
8. Buljan M, Situm M, Bolanca Z, Zivkovic MV, Mihic 
Buljan et al. Acta Dermatovenerol Croat
Disease progression in multiple primary melanoma  2015;23(4):260-264
264 ACTA DERMATOVENEROLOGICA CROATICA
LL. Multiple primary melanoma: epidemiological 
and prognostic implications; analysis of 36 cases. 
Coll Antropol 2010;Suppl 2:131-4.
9. Frank W, Rogers GS. Melanoma update. Second 
primary melanoma. J Dermatol Surg Oncol 
1993;19:427-30.
10. Slingluff CL, Jr., Vollmer RT, Seigler HF. Multiple 
primary melanoma: incidence and risk factors in 
283 patients. Surgery 1993;113:330-9.
11. Murali R, Goumas C, Kricker A, From L, Busam KJ, 
Begg CB, et al. Clinicopathologic features of in-
cident and subsequent tumors in patients with 
multiple primary cutaneous melanomas. Ann 
Surg Oncol 2012;19:1024-33.
12. Moscarella E, Rabinovitz H, Puig S, Zalaudek I, 
Oliviero MC, Brown L, et al. Multiple primary me-
lanomas: do they look the same? Br J Dermatol 
2013;168:1267-72.
13. Kricker A, Armstrong BK, Goumas C, Thomas NE, 
From L, Busam K, et al. Survival for patients with 
single and multiple primary melanomas: the ge-
nes, environment, and melanoma study. JAMA 
Dermatol 2013;149:921-7.
14. Blackwood MA, Holmes R, Synnestvedt M, Young 
M, George C, Yang H, et al. Multiple primary mela-
noma revisited. Cancer 2002;94:2248-55.
15. Doubrovsky A, Menzies SW. Enhanced survival in 
patients with multiple primary melanoma. Arch 
Dermatol 2003;139:1013-8.
16. Titus-Ernstoff L, Perry AE, Spencer SK, Gibson J, 
Ding J, Cole B, et al. Multiple primary melanoma: 
two-year results from a population-based study. 
Arch Dermatol 2006;142:433-8.
17. Burden AD, Newell J, Andrew N, Kavanagh G, Con-
nor JM, MacKie RM. Genetic and environmental 
influences in the development of multiple prima-
ry melanoma. Arch Dermatol 1999;135:261-5.
18. McMeniman E, De’Ambrosis K, De’Ambrosis B. Risk 
factors in a cohort of patients with multiple prima-
ry melanoma. Australas J Dermatol 2010;51:254-
7.
19. Conrad N, Leis P, Orengo I, Medrano EE, Hayes TG, 
Baer S, et al. Multiple primary melanoma. Der-
matol Surg 1999;25:576-81.
20. Burden AD, Vestey JP, Sirel JM, Aitchison TC, Hun-
ter JA, MacKie RM. Multiple primary melanoma: 
risk factors and prognostic implications. BMJ 
1994;309:375.
21. DiFronzo LA, Wanek LA, Morton DL. Earlier diag-
nosis of second primary melanoma confirms the 
benefits of patient education and routine posto-
perative follow-up. Cancer 2001;91:1520-4.
22. de Giorgi V, Rossari S, Papi F, Gori A, Alfaioli B, 
Grazzini M, et al. Multiple primary melanoma: the 
impact of atypical naevi and follow up. Br J Der-
matol 2010;163:1319-22.
23. Manganoni AM, Farisoglio C, Tucci G, Facchetti F, 
Calzavara Pinton PG. The importance of self-exa-
mination in the earliest diagnosis of multiple pri-
mary cutaneous melanomas: a report of 47 cases. 
J Eur Acad Dermatol Venereol 2007;21:1333-6.
Buljan et al. Acta Dermatovenerol Croat
Disease progression in multiple primary melanoma  2015;23(4):260-264
